ABCL Key Statistics, Chart & Performance
The current stock price of ABCL is 3.42 USD. In the past month the price decreased by -1.16%. In the past year, price increased by 9.27%.
ABCL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.87 | 217.71B | ||
| DHR | DANAHER CORP | 29.69 | 161.70B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 183 | 55.61B | ||
| A | AGILENT TECHNOLOGIES INC | 24.39 | 38.58B | ||
| IQV | IQVIA HOLDINGS INC | 19.38 | 38.39B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.32 | 28.48B | ||
| WAT | WATERS CORP | 29.91 | 22.61B | ||
| ILMN | ILLUMINA INC | 30.08 | 20.04B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.92 | 19.79B | ||
| MEDP | MEDPACE HOLDINGS INC | 39.28 | 15.82B | ||
| RVTY | REVVITY INC | 20.2 | 10.97B | ||
| TEM | TEMPUS AI INC | N/A | 10.51B |
Related stock screener links
About ABCL
Company Profile
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 596 full-time employees. The company went IPO on 2020-12-11. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. The company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Company Info
ABCELLERA BIOLOGICS INC
150 W 4Th Avenue
Vancouver BRITISH COLUMBIA CA
Employees: 596
Phone: 16045599005
ABCELLERA BIOLOGICS INC / ABCL FAQ
What does ABCELLERA BIOLOGICS INC do?
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 596 full-time employees. The company went IPO on 2020-12-11. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. The company is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
What is the current price of ABCL stock?
The current stock price of ABCL is 3.42 USD. The price decreased by -0.87% in the last trading session.
What is the dividend status of ABCELLERA BIOLOGICS INC?
ABCL does not pay a dividend.
What is the ChartMill technical and fundamental rating of ABCL stock?
ABCL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does ABCELLERA BIOLOGICS INC have?
ABCELLERA BIOLOGICS INC (ABCL) currently has 596 employees.
What is the ownership structure of ABCELLERA BIOLOGICS INC (ABCL)?
You can find the ownership structure of ABCELLERA BIOLOGICS INC (ABCL) on the Ownership tab.
ABCL Technical Analysis
ABCL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABCL. No worries on liquidiy or solvency for ABCL as it has an excellent financial health rating, but there are worries on the profitability.
ABCL Financial Highlights
Over the last trailing twelve months ABCL reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS increased by 6.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.66% | ||
| ROE | -17.81% | ||
| Debt/Equity | 0 |
ABCL Forecast & Estimates
14 analysts have analysed ABCL and the average price target is 10.03 USD. This implies a price increase of 193.27% is expected in the next year compared to the current price of 3.42.
For the next year, analysts expect an EPS growth of -22.09% and a revenue growth 12.29% for ABCL